Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Telemedicine in Primary Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients that are attributed to primary care clinics across four health systems in the INSIGHT (Mount Sinai Health System and Weill Cornell Medicine), OneFlorida (University of Florida Health), and STAR (University of North Carolina Health) CRNs.~* Patients received two or more outpatient visits at a participating practice during a one-year period before the COVID-19 pandemic,~* Patients had one or more of five chronic illnesses (asthma, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), diabetes, hypertension) as defined by the Medicare Chronic Conditions Warehouse algorithm~Exclusion Criteria:~* Patients who tested COVID-positive~* Patients from hospice and palliative care practices~* Patients from osteopathic medicine practices~* Patients from pediatric practices~* Patients that did not reside in states where the four health systems were located: the New York-Tri State Area (Connecticut, New York, and New Jersey), Florida, and North Carolina.~* Patients that moved out of state (or out of the New York-Tri State Area) or who died during the study period were also excluded.~* Patients who were not continuously enrolled over the entire study period (2019-2021).

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- High Telemedicine (Type: None): Patients in practices that had high telemedicine use, based on the percent of visits the practice delivered via telemedicine from April 2020 to December 2021 (the study post-period)
- Low Telemedicine (Type: None): Patients in practices that had some telemedicine use, based on the percent of visits the practice delivered via telemedicine from April 2020 to December 2021 (the study post-period)

Based on this trial design, predict the completion outcome and termination type (if applicable).